Advertisement
UK markets close in 7 hours 48 minutes
  • FTSE 100

    8,172.12
    +25.26 (+0.31%)
     
  • FTSE 250

    20,207.43
    +87.07 (+0.43%)
     
  • AIM

    778.06
    +2.02 (+0.26%)
     
  • GBP/EUR

    1.1838
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2666
    -0.0020 (-0.16%)
     
  • Bitcoin GBP

    52,262.00
    -31.74 (-0.06%)
     
  • CMC Crypto 200

    1,393.17
    +5.01 (+0.36%)
     
  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     
  • DOW

    38,589.16
    -57.94 (-0.15%)
     
  • CRUDE OIL

    78.42
    -0.03 (-0.04%)
     
  • GOLD FUTURES

    2,334.00
    -15.10 (-0.64%)
     
  • NIKKEI 225

    38,102.44
    -712.12 (-1.83%)
     
  • HANG SENG

    17,939.90
    -1.88 (-0.01%)
     
  • DAX

    18,130.74
    +128.72 (+0.72%)
     
  • CAC 40

    7,569.33
    +66.06 (+0.88%)
     

Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024

Vericel Corporation
Vericel Corporation

CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO and Joe Mara, CFO will participate in a fireside chat at the Leerink Partners Healthcare Crossroads Conference at 9:40 a.m. ET on Wednesday, May 29, 2024.

A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.

About Vericel Corporation

Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel also holds an exclusive license for North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns. For more information, please visit www.vcel.com.

ADVERTISEMENT

Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2024 Vericel Corporation. All rights reserved.

Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411

Media Contact: 
Julie Downs
media@vcel.com